Abstract |
The P2X7 receptor (P2X7R) is a key neuroinflammation target in a variety of neurodegenerative diseases. Improved radiosynthesis was developed according to the previously reported P2X7R antagonist GSK1482160. Biodistribution, radiometabolite, and dynamic positron emission tomography/computed tomography-magnetic resonance imaging (PET/CT-MRI) of the lipopolysaccharide (LPS) rat model and the transgenic mouse model of Alzheimer's disease (AD) revealed a stable, low uptake of [18F]4A in the brain of healthy rats but a higher standardized uptake value ratio (SUVR) in LPS-treated rats (1.316 ± 0.062, n = 3) than in sham (1.093 ± 0.029, n = 3). There were higher area under curves (AUCs) in the neocortex (25.12 ± 1.11 vs 18.94 ± 1.47), hippocampus (22.50 ± 3.41 vs 15.90 ± 1.59), and basal ganglia (22.26 ± 0.81 vs 15.32 ± 1.76) of AD mice (n = 3) than the controls (n = 3) (p < 0.05). Furthermore, 50 min dynamic PET in healthy nonhuman primates (NHPs) indicated [18F]4A could penetrate the blood-brain barrier (BBB). In conclusion, [18F]4A from this study is a potent P2X7R PET tracer that warrants further neuroinflammation quantification in human studies.
|
Authors | Guolong Huang, Yifan Qiu, Lei Bi, Huiyi Wei, Guocong Li, Zhijun Li, Peizhen Ye, Min Yang, Yanfang Shen, Hao Liu, Lu Wang, Hongjun Jin |
Journal | ACS chemical neuroscience
(ACS Chem Neurosci)
Vol. 13
Issue 23
Pg. 3464-3476
(12 07 2022)
ISSN: 1948-7193 [Electronic] United States |
PMID | 36441909
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Receptors, Purinergic P2X7
|
Topics |
- Animals
- Mice
- Rats
- Receptors, Purinergic P2X7
- Positron Emission Tomography Computed Tomography
- Tissue Distribution
|